To include your compound in the COVID-19 Resource Center, submit it here.

HATs off to epigenetics

How AbbVie is expanding its reach in cancer epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an inhibitor of two histone acetyltransferases, a class of epigenetic enzymes largely untouched by drug developers.

In a paper published in Nature last month,

Read the full 581 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers